Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633360 · ClinicalTrials.gov registry record · NA
The Oral Contraceptive Pill for Premenstrual Worsening of Depression
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00633360: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00633360 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00633360, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
To determine if augmentation with the oral-contraceptive pill containing drospirenone and ethinyl estradiol is more effective than placebo in the treatment of premenstrual breakthrough of depression.
Interventions
- DRUG Placebo
- DRUG Drospirenone and ethinyl estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633360
The ClinicalTrials.gov registry entry for NCT00633360 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00633360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633360 about?
NCT00633360 is a clinical study titled "The Oral Contraceptive Pill for Premenstrual Worsening of Depression". To determine if augmentation with the oral-contraceptive pill containing drospirenone and ethinyl estradiol is more effective than placebo in the treatment of premenstrual breakthrough of depression.
What is the current status of trial NCT00633360?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2008-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00633360?
The interventions under investigation include: Placebo (DRUG), Drospirenone and ethinyl estradiol (DRUG).
Who is sponsoring clinical trial NCT00633360?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.